logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Vabp

    FiltersReset Filters
    6 results

    • avycaz

      (ceftazidime, avibactam)
      Allergan, Inc.
      Usage: AVYCAZ (ceftazidime and avibactam) is indicated for treating complicated intra-abdominal and urinary tract infections, including pyelonephritis, as well as hospital-acquired and ventilator-associated bacterial pneumonia. It targets susceptible gram-negative bacteria in adult and pediatric patients (≥31 weeks gestational age).

    • fetroja

      (Cefiderocol sulfate tosylate)
      Shionogi Inc.
      Usage: FETROJA® is indicated for patients aged 18 and older for treating complicated urinary tract infections (cUTIs) including pyelonephritis, and hospital-acquired/ventilator-associated bacterial pneumonia, caused by susceptible Gram-negative bacteria like E. coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Use should limit drug resistance.

    • recarbrio

      (imipenem anhydrous, cilastatin, and relebactam anhydrous)
      Merck Sharp & Dohme LLC
      Usage: RECARBRIO is indicated for treating adults with hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, complicated urinary tract infections, and complicated intra-abdominal infections caused by specific susceptible gram-negative bacteria, particularly when limited treatment options exist. Its use aims to combat drug-resistant bacterial development.

    • vibativ

      (telavancin hydrochloride)
      Cumberland Pharmaceuticals Inc.
      Usage: VIBATIV is indicated for adults with complicated skin and skin structure infections (cSSSI) and hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible Gram-positive organisms, including methicillin-susceptible and -resistant Staphylococcus aureus. It may be used as empiric therapy in certain cases.

    • xacduro

      (sulbactam and durlobactam)
      LaJolla Pharmaceutical Company
      Usage: XACDURO is indicated for treating hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in adults, caused by susceptible strains of Acinetobacter baumannii-calcoaceticus. It should only be used for infections proven or suspected to be due to these bacteria to prevent drug resistance.

    • zerbaxa

      (ceftolozane and tazobactam)
      Merck Sharp & Dohme LLC
      Usage: ZERBAXA is indicated for the treatment of complicated intra-abdominal infections, complicated urinary tract infections (including pyelonephritis), and hospital-acquired or ventilator-associated bacterial pneumonia in adults and pediatric patients, targeting specific susceptible Gram-negative and Gram-positive bacteria. Usage should be guided by culture results and epidemiology.